CA-AKTANA
4.5.2022 13:57:13 CEST | Business Wire | Press release
Aktana , the leader in intelligent customer engagement for the global life sciences industry, announced that Almirall, LLC selected its Contextual Intelligence Engine for nationwide rollout across two leading brands in the United States. The global skin health leader deployed Aktana’s solution in early January and is already outpacing expectations with 86% rep engagement and a sharp increase in rep productivity. Aktana’s Contextual Intelligence 360 is a modular solution that enables commercial and medical teams to rapidly scale AI-driven programs that personalize the customer experience, coordinate engagement, and optimize the entire HCP journey across channels.
With more than 300 deployments across 50+ use cases, Aktana has been refining its commercial life sciences intelligence platform for more than a decade. More than half of the world's top-20 pharmaceutical companies rely on Aktana to coordinate and optimize personalized omnichannel engagement with HCPs. With their recent deployment, Almirall now joins this group of industry innovators using Aktana’s modular AI solution to transform their commercial approach.
“We aim to be the global leader in medical dermatology and intend to act like a leader by replacing clunky processes with agile, best-in-class technologies,” said Vincent Cerio, head of commercial operations at Almirall. “We have seen swift and remarkable results. Our teams have embraced Aktana’s Contextual Intelligence 360 solution, seeing the impact on customer engagement and individual productivity. The rep locator module, for instance – which predicts how far HCPs will be from a rep’s expected location – has helped reps optimize their days, minimizing ‘windshield’ time.”
Change management is another critical aspect of AI adoption. Aktana incorporates change management functionality into its engine, such as seamless workflow integration and transparent suggestion logic, to build user confidence and accelerate onboarding. “At Aktana’s suggestion, we also invested in a formal change management program grounded in ongoing, honest communication. A team of early adopters provided feedback and served as internal champions, inspiring others to use Aktana’s system and experience the same benefits they were experiencing,” explained Cerio. “User acceptance has been great, so we want to expand our use of the system in various ways – from content optimization to next-best-action suggestions for our medical science liaisons.”
Contextual Intelligence 360 is powered by Aktana’s next-generation Contextual Intelligence Engine , which applies machine learning, explainable AI (xAI), human intelligence, and other advanced technologies to mine data and insights from all sources – from prescribing habits and patient demographics to past brand interactions and field rep insights. Dynamic, real-time recommendations ensure field and marketing teams work together to create meaningful HCP partnerships that continuously evolve.
“As a fast-growing medical dermatology company, Almirall recognizes the urgency and importance of leveraging advanced AI technology to empower its commercial teams,” said Derek Choy, president of Aktana. “With its flexible architecture, Aktana’s Contextual Intelligence 360 made it possible for Almirall to implement quickly while laying the foundation to scale into other areas and geographies when they’re ready to expand.”
About Aktana
Aktana is the category creator and leader of intelligent engagement in the global life sciences industry. By ensuring that every customer experience is tailored to individual preferences and needs, Aktana helps life science companies strengthen their relationships with healthcare providers to inspire better patient care. Today, commercial and medical teams from more than 300 brands use Aktana’s AI-enabled Contextual Intelligence Engine to coordinate and optimize personalized omnichannel engagement at scale. More than half of the top-20 global pharmaceutical companies are Aktana customers. Headquartered in San Francisco, Aktana has offices in every major biopharma region around the world. For more information, visit www.aktana.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220504005413/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTM Collaborates with IBM and Red Hat on Lightwell to Advance AI-Driven Open-Source Software Remediation9.9.2026 14:30:00 CEST | Press release
Strengthens software supply chains by helping enterprises transform vulnerability discovery into scalable remediation outcomes LTM, the Business Creativity partner to the world's largest enterprises, today announced that it has collaborated with IBM and Red Hat on Lightwell to help enterprises safeguard the open-source software supply chain through AI-driven vulnerability remediation. As AI accelerates the discovery of software vulnerabilities, organizations must move beyond detection-focused approaches and adopt enterprise-scale remediation strategies that enable rapid risk mitigation without disrupting business-critical applications. Lightwell’s approach of delivering validated fixes for production environments aligns with LTM's aim of helping customers build secure, resilient, and operationally efficient software supply chains. By combining AI-powered remediation capabilities with enterprise-grade validation and deployment support, Lightwell aims to help organizations address securi
New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life9.9.2026 14:24:00 CEST | Press release
Data Demonstrated Significant and Clinically Meaningful Improvements with the Potential to Redefine Narcolepsy Type 1 (NT1) Care Beyond Individual Symptoms Oveporexton was Generally Well-Tolerated with Safety Profile Consistent with Previous Clinical Studies Oveporexton is the First and Only Approved Orexin Agonist Designed to Treat the Underlying Cause of NT1 and is Now Approved in the U.S., China and Japan, with Additional Regulatory Submissions Underway Takeda (TSE:4502/NYSE:TAK) announced that the New England Journal of Medicine published results from two Phase 3 studies evaluating oveporexton (ORZEYFUL), an oral orexin receptor 2 (OX2R) agonist, in people with narcolepsy type 1 (NT1).1 Oveporexton is the first and only medicine to treat the underlying cause of NT1. "People living with narcolepsy type 1 face persistent symptoms across the day and night, which can impact many aspects of daily life,” said Emmanuel Mignot, M.D., Ph.D., principal investigator for the FirstLight (TAK-86
ZincFive Launches Next-Generation BMS, Setting a New Standard for Nickel-Zinc Battery Management9.9.2026 14:05:00 CEST | Press release
Purpose-built Battery Management System (BMS) streamlines installation and supports the evolving power demands of AI data centers ZincFive®, the leader in nickel-zinc (NiZn) battery-based solutions for immediate power applications, today launched the ZincFive BMS, a next-generation battery management system purpose-built for its NiZn chemistry, designed and assembled in the U.S. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260909653032/en/ The ZincFive BMS ships standard with every ZincFive BC Series UPS Battery Cabinets, serving as the primary interface for data center operators, UPS OEM partners, and system integrators to monitor and manage ZincFive’s technology. Built on years of experience managing NiZn in real-world data center environments, ZincFive engineered the BMS around the unique characteristics of its NiZn chemistry, rather than adapting a platform designed for lithium-ion or lead-acid batteries. The result is
EIG Announces Final Close of Senior Infrastructure Debt Fund VI With $4.0 Billion Raised Across Its Direct Lending Platform9.9.2026 14:00:00 CEST | Press release
Platform exceeds original $3 billion fundraising target, reflecting broad institutional demand for infrastructure credit EIG, a leading institutional investor in the global energy and infrastructure sectors, today announced the final close of EIG Senior Infrastructure Debt Fund VI (“SIDF VI”) at $1.9 billion, nearly double the size of its predecessor fund. Together with $2.1 billion committed to single investor vehicles, this exceeds the strategy's original $3 billion target and reflects strong demand from investors seeking customized and evergreen exposure to senior infrastructure debt. Since launching in July 2024, SIDF VI has already committed approximately $1 billion across 16 investments, reflecting strong proprietary origination capabilities. SIDF VI seeks to make directly originated, senior secured debt investments across a broad range of sectors, including power generation, renewable energy, energy transition infrastructure, midstream and other critical infrastructure, with a p
CoreTrust Expands International Presence, Extends Global Procurement Platform Across Europe9.9.2026 14:00:00 CEST | Press release
CoreTrust Europe unlocks new growth opportunities for global supplier partners, bringing measurable savings and operational leverage to multinational corporations operating across borders CoreTrust, a premier group purchasing organization (GPO) with more than 20 years of leveraging data-driven procurement intelligence and $7 billion in aggregated spend, today announced the expansion of CoreTrust Europe and its procurement platform to the United Kingdom and key European markets, including France, Germany, Ireland, the Netherlands, Sweden, and Switzerland. While members can enroll when headquartered in these seven markets, CoreTrust’s supplier partners deliver negotiated coverage that reaches members well beyond them. This strategic international expansion answers direct demand from CoreTrust’s private equity partners and multinational members to extend the company’s proven model into large, still-underserved European markets — the same demand-led path CoreTrust has followed for nearly t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
